Ezetimibe for Patients With Chronic Hepatitis D

Chronic Hepatitis D Clinical Trial

Official title:
Ezetimibe for Patients With Chronic Hepatitis D

Status Recruiting

Clinical Trial Summary

Ezetimibe possesses pharmacophore features to inhibit NTCP, the receptor required for HBV and HDV hepatocyte entry that include two hydrophobes and one hydrogen bond acceptor. Therapy with Ezetimibe may lead to decline in hepatitis D virus levels. The aim of the study is to evaluate the utility of Ezetimibe in patients with chronic HDV infection

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03099278
Study type	Interventional
Source	Ziauddin Hospital
Contact	Zaigham Abbas
Phone	922135862937
Email	drzabbas@gmail.com
Status	Recruiting
Phase	Phase 2
Start date	January 2017
Completion date	October 2017

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06051045` - Study to Evaluate Efficacy, Safety and Biomarkers of Bulevirtide Treatment in Chronic Hepatitis D Patients
Recruiting	`NCT00117533` - Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta	Phase 4
Completed	`NCT00001457` - Lamivudine for Chronic Hepatitis B	Phase 2
Recruiting	`NCT06121427` - Incidence of Viral Hepatitis D Relapses Upon Discontinuation of Bulevirtide in Patients With Chronic Hepatitis D and Negative HDV RNA
Recruiting	`NCT05723068` - Burden of Hepatitis D Virus (HDV) Infection in Italy